Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12224068 | 0.82 | LMNA (0.47) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL2988177 | 0.80 | ELANE (0.40) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL4737400 | 0.80 | ELANE (0.40) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL2990590 | 0.80 | ELANE (0.40) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL6892654 | 0.79 | MMP1 (0.59) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL10875539 | 0.78 | ELANE (0.39) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL10550620 | 0.78 | ELANE (0.39) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL9098648 | 0.78 | ELANE (0.39) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL4740135 | 0.78 | ELANE (0.39) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL13335494 | 0.78 | MMP1 (0.40) | MMP1MMP2MMP3MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723728-B2 | Prodrugs of Nh-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723728-B2 | Prodrugs of Nh-acidic compounds | SI, NAAA, NIT2 | MMP1 551/4885MMP2 1550/4885MMP3 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.